These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9707028)

  • 1. Activated peripheral blood mononuclear cells from patients receiving subcutaneous interleukin-2 following autologous stem cell transplantation prolong survival of SCID mice bearing human lymphoma.
    Katsanis E; Weisdorf DJ; Miller JS
    Bone Marrow Transplant; 1998 Jul; 22(2):185-91. PubMed ID: 9707028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
    Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
    Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
    Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
    Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
    Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor therapeutic potential of activated human umbilical cord blood cells against leukemia and breast cancer.
    Joshi SS; Tarantolo SR; Kuszynski CA; Kessinger A
    Clin Cancer Res; 2000 Nov; 6(11):4351-8. PubMed ID: 11106253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antilymphoma activity of human gamma delta T-cells in mice with severe combined immune deficiency.
    Malkovska V; Cigel FK; Armstrong N; Storer BE; Hong R
    Cancer Res; 1992 Oct; 52(20):5610-6. PubMed ID: 1394184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency.
    Hill LL; Perussia B; McCue PA; Korngold R
    Cancer Res; 1994 Feb; 54(3):763-70. PubMed ID: 8306339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 4 retards dissemination of a human B-cell lymphoma in severe combined immunodeficient mice.
    Schwarz MA; Tardelli L; Macosko HD; Sullivan LM; Narula SK; Fine JS
    Cancer Res; 1995 Sep; 55(17):3692-6. PubMed ID: 7641177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
    Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
    Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
    Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
    Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
    Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
    Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model.
    Alici E; Konstantinidis KV; Sutlu T; Aints A; Gahrton G; Ljunggren HG; Dilber MS
    Exp Hematol; 2007 Dec; 35(12):1839-46. PubMed ID: 18036444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of recombinant human prolactin in human adenocarcinoma-bearing SCID mice with human NK cell xenograft.
    Zhang J; Sun R; Wei H; Tian Z
    Int Immunopharmacol; 2005 Feb; 5(2):417-25. PubMed ID: 15652770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.